| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ee2b4cf5180521e069e04d91bced4ff1 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-41
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-732
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-90
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-5443
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-2086
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2809
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-3092
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2019-03-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_53cfe270f6644a727df1c61bc32653cb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3fd6b332c998a6a6fed397b260d0798e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_46786a1a22b11cf9604874405472f291
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b3aadff4ba8bbe423970282e44228455
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_99b4f8a9cf529fb3405ee7ad1e1c2998
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_369e14851097cf26ecfb09c52732b78a |
| publicationDate |
2021-01-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3759144-A1 |
| titleOfInvention |
Fusion protein constructs comprising an anti-muc1 antibody and il-15 |
| abstract |
The present invention pertains to fusion protein constructs comprising an antibody against the cancer antigen MUC1 and IL-15. In particular, the fusion protein constructs activate NK cells and T cells at the cancer site. |
| priorityDate |
2018-03-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |